Eupraxia Pharmaceuticals (EPRX) announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia Pharmaceuticals to Showcase EP-104GI Data at Digestive Disease Week 2026
- Eupraxia Pharmaceuticals: Strong EP-104GI Clinical Durability and Dose-Response Support Buy Rating and Favorable Risk-Reward
- Eupraxia Posts Strong 36-Week EoE Data From Highest-Dose Cohort in RESOLVE Trial
- Encouraging EP-104GI EoE Data and Strong Cash Runway Underpin Buy Rating on Eupraxia
- Compelling EP‑104GI Eosinophilic Esophagitis Data and Safety Profile Underpin Buy Rating and Attractive Risk‑Reward Ahead of Phase IIb Catalysts